MARI Stock Overview
A biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Marinomed Biotech AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €13.10 |
| 52 Week High | €44.80 |
| 52 Week Low | €12.30 |
| Beta | 0.025 |
| 1 Month Change | -22.71% |
| 3 Month Change | -36.41% |
| 1 Year Change | -69.75% |
| 3 Year Change | -89.31% |
| 5 Year Change | -83.52% |
| Change since IPO | -82.76% |
Recent News & Updates
A Look At The Fair Value Of Marinomed Biotech AG (VIE:MARI)
May 25
Marinomed Biotech AG (VIE:MARI) Could Be Riskier Than It Looks
Feb 03Recent updates
A Look At The Fair Value Of Marinomed Biotech AG (VIE:MARI)
May 25Marinomed Biotech AG (VIE:MARI) Could Be Riskier Than It Looks
Feb 03Marinomed Biotech AG (VIE:MARI) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Apr 22Marinomed Biotech AG's (VIE:MARI) Analyst Just Slashed This Year's Estimates
Sep 22Shareholder Returns
| MARI | AT Pharmaceuticals | AT Market | |
|---|---|---|---|
| 7D | 2.3% | 2.3% | 0.3% |
| 1Y | -69.7% | 20.3% | 8.7% |
Price Volatility
| MARI volatility | |
|---|---|
| MARI Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in AT Market | 6.0% |
| 10% least volatile stocks in AT Market | 1.5% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 44 | Andreas Grassauer | www.marinomed.com |
Marinomed Biotech AG, a biopharmaceutical company, develops therapeutic products for indications in virology and immunology in Austria, other European countries, and internationally. The company operates through Virology, Immunology, and Other segments. Its products pipeline includes Budesolv for the treatment of allergic rhinitis; Tacrosolv, which is in Phase II clinical trial for inflammatory eye diseases; Carravin for the treatment of nasal congestion; and Inhaleen for viral pneumonia, as well as Carragelose, which consists of nasal and throat sprays, and lozenges for treating viral respiratory infections.
Marinomed Biotech AG Fundamentals Summary
| MARI fundamental statistics | |
|---|---|
| Market cap | €19.95m |
| Earnings (TTM) | -€6.87m |
| Revenue (TTM) | €6.60m |
3.1x
P/S Ratio-2.9x
P/E RatioIs MARI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MARI income statement (TTM) | |
|---|---|
| Revenue | €6.60m |
| Cost of Revenue | €6.19m |
| Gross Profit | €411.30k |
| Other Expenses | €7.28m |
| Earnings | -€6.87m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 20, 2024
| Earnings per share (EPS) | -4.46 |
| Gross Margin | 6.23% |
| Net Profit Margin | -103.99% |
| Debt/Equity Ratio | -183.6% |
How did MARI perform over the long term?
See historical performance and comparison